Clin Assoc Prof Chay Wen Yee

Dr Chay Wen Yee is a Senior consultant Medical Oncologist at National Cancer Centre Singapore with an interest in gynaecological cancers and breast cancer. She is also a visiting consultant at the Department of Gynecological Oncology, KK Women and Children’s Hospital as well as a Clinical Assistant Professor, Department of Medicine, Singhealth Duke-NUS Oncology Academic Clinic Programme.

Dr Chay’s research interests lie mainly in gynecological cancers particularly in the identification of biomarkers in mucinous ovarian cancer. She is involved in various investigator initiated as well as in-dustry sponsored trials, both in the capacity of principal investigator and co-investigator. She is a keen educator and is active in both undergraduate and post graduate teaching, previously as Core Faculty, Senior Residency Programme (Medical Oncology) as well as faculty for Duke-NUS Gradu-ate Medical School and clinical tutor for Yong Loo Lin School of Medicine.

• Master of Medicine (Internal  Medicine), Singapore National University of Singapore, 2007
• MRCP ( UK) 2007
• MBBS, National University of Singapore 2004

• Chapter of Medical Oncology, Academy of Medicine Singapore,  Committee Member 2019-  Present
• Gynaecologic Cancer Group Singapore Council Member 2018 - Present
• Singapore Cancer Society Women’s Gynaecological Cancers Committee :  Member  2017 –Present
• Academy of Medicine Singapore Member 2012 - Present
• Singapore Society of Oncology Member 2010-  Present

• SingHealth Best Medical Officer Award 2008 
• FY 2014 Health Manpower Development Plan ( HMDP ) Clinical Fellowship in Comprehensive Gynaecology Oncology, BC Cancer Agency, Vancouver, Canada
  

• Chin F, Ee TX, Goh C, Ng QJ, Low J, Chan J, Chay WY, Ho WY, Wang J, Aggarwal I, Phoon J. EP184/# 803 Oncofertility in ovarian tumors at a tertiary referral centre in Singa-pore. International Journal of Gynecologic Cancer. 2023 November; 33(4). JIF: NA Times Cited: 0 
• Ngoi N, Sun H, Choi CH, Heong V, Ow SGW, Chay WY, Kim HS, Goss G, Goh J, Lin M, Lim D, Kim JW, Friedlander M, Tai BC, Kim K, Tan DSP. Quality of Life (QoL) in patients with recurrent ovarian clear cell carcinoma receiving durvalumab (D) versus physician’s choice chemotherapy in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial. Journal of Clinical Oncology. 2023 Jun; 41 (16) JIF: NA Times Cited: 0 
• Min LT, Zhou S, Phyu N, Ishak HMM, Yang CS, Kusumawidjaja G, Chay WY, Wong FY, Wong RX. Neutrophil/lymphocyte ratio (NLR) and albumin-globulin ratio (AGR): Correla-tions with outcomes in patients with stage I-III breast cancer. Journal of Clinical Oncology. 2023 Jun; 41 (16) JIF: NA Times Cited: 0 
• S. Koppikar, A. Oaknin, K. Govind Babu, D. Lorusso, S. Gupta, L.-Y. Wu, W. Rajabto, K. Harano, S.-H. Hong, R.A. Malik, H. Strebel, I.M. Aggarwal, C.H. Lai, T. Dejthevaporn, S. Tangjitgamol, W.F. Cheng, W.Y. Chay, D. Benavides, N.M. Hashim, Y.W. Moon, M. Yunokawa, T.D. Anggraeni, W. Wei, G. Curigliano, A. Maheshwari, U. Mahantshetty, S. Sheshadri, S. Peters, T. Yoshino, G. Pentheroudakis. Pan-Asian adapted ESMO Clinical Prac-tice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial can-cer. ESMO Open. 2023 Feb. Volume 8, Issue 1, 100774.JIF: NA Times Cited: 0